

台灣癌症登記中心通知

急件

發件人： 台灣癌症登記中心
電話： 02-2341-6012
傳真： 02-2351-1733
地址： 100 台北郵政 84-310 信箱
日期： 109 年 3 月 23 日
編號： 癌登第 109001-1 號

收文者： 所有申報醫院

副本收文者： 衛生福利部國民健康署、台灣癌症登記學會、資拓宏宇國際股份有限公司

主 題： 修正有關子宮頸癌2018年版FIGO期別登錄方式，請 貴院依說明段辦理

急件 請檢閱 請加註 請回覆 請回收

- 一、 本案係依衛生福利部國民健康署委託「台灣癌症登記工作計畫」辦理。
- 二、 子宮頸癌 2018 年版 FIGO 期別定義如下，表格摘錄自 International Journal of Gynecology & Obstetrics 2018; 143 (Suppl. 2): 22-36。

TABLE 1 FIGO staging of cancer of the cervix uteri (2018).

Stage	Description
I	The carcinoma is strictly confined to the cervix (extension to the uterine corpus should be disregarded)
IA	Invasive carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion <5 mm ^a
IA1	Measured stromal invasion <3 mm in depth
IA2	Measured stromal invasion ≥3 mm and <5 mm in depth
IB	Invasive carcinoma with measured deepest invasion ≥5 mm (greater than Stage IA), lesion limited to the cervix uteri ^b
IB1	Invasive carcinoma ≥5 mm depth of stromal invasion, and <2 cm in greatest dimension
IB2	Invasive carcinoma ≥2 cm and <4 cm in greatest dimension
IB3	Invasive carcinoma ≥4 cm in greatest dimension
II	The carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall
IIA	Involvement limited to the upper two-thirds of the vagina without parametrial involvement
IIA1	Invasive carcinoma <4 cm in greatest dimension
IIA2	Invasive carcinoma ≥4 cm in greatest dimension
IIB	With parametrial involvement but not up to the pelvic wall
III	The carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or nonfunctioning kidney and/or involves pelvic and/or para-aortic lymph nodes ^c
IIIA	The carcinoma involves the lower third of the vagina, with no extension to the pelvic wall
IIIB	Extension to the pelvic wall and/or hydronephrosis or nonfunctioning kidney (unless known to be due to another cause)
IIIC	Involvement of pelvic and/or para-aortic lymph nodes, irrespective of tumor size and extent (with r and p notations) ^c
IIIC1	Pelvic lymph node metastasis only
IIIC2	Para-aortic lymph node metastasis
IV	The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. (A bullous edema, as such, does not permit a case to be allotted to Stage IV)
IVA	Spread to adjacent pelvic organs
IVB	Spread to distant organs

When in doubt, the lower staging should be assigned.

^aImaging and pathology can be used, where available, to supplement clinical findings with respect to tumor size and extent, in all stages.

^bThe involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered.

^cAdding notation of r (imaging) and p (pathology) to indicate the findings that are used to allocate the case to Stage IIIC. Example: If imaging indicates pelvic lymph node metastasis, the stage allocation would be Stage IIIC1r, and if confirmed by pathologic findings, it would be Stage IIIC1p. The type of imaging modality or pathology technique used should always be documented.

三、 有關子宮頸癌 2018 年版 FIGO 期別登錄，國民健康署業於 108 年 1 月 24 日發文通知(國健癌字第 1080300146 號)，適用於 108 年起新診斷個案。因應新版 2018 年 FIGO 期別登錄，說明如下：

- (1) **FIGO 分期應用於子宮頸癌屬於臨床分期**。因 FIGO 2018 年版新增 IIIC 期別為淋巴結侵犯且需依**檢查證實方式**記錄 r(imaging)與 p(pathology)，此可參考前述第二點表格 1 內附註 C 說明。
- (2) 因應 FIGO 期別改版修訂內容，原訂 109 年第一季子宮頸癌個案資料，可延至 **109 年度第二季**再一併申報；然上述邏輯修訂，**即日起**一併更新上線，提供醫院進行勘誤。
- (3) 原癌登第 109001 通知文內提及「**臨床 IIIC1 或 IIIC2 由 p(pathology)檢查證實結果，登錄於其他分期系統期別(病理)欄位**」之規則**取消**，即 FIGO 期別僅須登錄於「**其他分期系統期別(臨床)**」欄位。

四、 有關子宮頸癌 FIGO 「其他分期系統期別(臨床)」欄位編碼原則如下：

- (1) 針對 FIGO stage IIIC 判定，r(imaging)應參考影像報告，p(pathology)可參考淋巴結切片或切除病理報告。
- (2) FIGO stage IIIC 個案須依據 r(imaging)或 p(pathology)證實方式，編碼為 IIIC1R、IIIC1P、IIIC2R 或 IIIC2P；若同時有影像與淋巴結切片/切除病理結果證實者，優先編碼為 IIIC1P 或 IIIC2P。
- (3) FIGO 編碼定義如下：

編碼	定義	編碼	定義	編碼	定義	編碼	定義
0	Stage 0	2	Stage II	3	Stage III	4	Stage IV
1	Stage I	2A	Stage IIA	3A	Stage IIIA	4A	Stage IVA
1A	Stage IA	2A1	Stage IIA1	3B	Stage IIIB	4B	Stage IVB
1A1	Stage IA1	2A2	Stage IIA2	3C	Stage IIIC	8888	不適用
1A2	Stage IA2	2B	Stage IIB	3CR	Stage IIICr	9999	不詳
1B	Stage IB	2C	Stage IIC	3CP	Stage IIICp		
1B1	Stage IB1			3C1R	Stage IIIC1r		
1B2	Stage IB2			3C1P	Stage IIIC1p		
1B3	Stage IB3			3C2R	Stage IIIC2r		
1C	Stage IC			3C2P	Stage IIIC2p		

(4) 若個案已侵犯鄰近骨盆腔器官或遠端轉移者，即使區域淋巴結有侵犯，仍應以 FIGO stage IV 申報。

(5) 以 FIGO stage I-III C 申報舉例如下：

	首次治療前			FIGO 期別
	執行影像檢查	執行淋巴結切片/切除	區域淋巴結檢查結果	其他分期系統期別(臨床)欄位
案例 1	有	無	未侵犯	I-III B
案例 2	有	有	未侵犯	I-III B
案例 3	有	無	有侵犯	IIIC1R or IIIC2R
案例 4	有	有	有侵犯	IIIC1P or IIIC2P

五、 前述新增欄位內容將納入於 109 年底公告之「107 年版台灣癌症登記摘錄手冊 v.3」內。

六、 若於本次修正通知文公告前，已申報子宮頸癌 FIGO stage III C 個案者，請依據本次修正內容進行申報資料異動作業；另本中心將於 4 月份進行年報複查退件時，一併提供前述「108 診斷年 FIGO stage III C 個案已申報尚未異動名單」，屆時請協助處理。